Literature DB >> 35092687

Approach to the Patient: Differential Diagnosis of Cystic Sellar Lesions.

Mônica R Gadelha1,2,3, Luiz Eduardo Wildemberg1,3, Elisa Baranski Lamback1,2,3, Monique Alvares Barbosa4,5,6, Leandro Kasuki1,3,7, Nina Ventura4,8,9.   

Abstract

Cystic lesions arising in the sellar region are not uncommon and encompass cystic pituitary adenomas, Rathke cleft cysts, craniopharyngiomas, and arachnoid cysts. Their clinical presentation may be similar, including headache, visual field defects, and anterior pituitary hormone deficits, which makes differential diagnosis challenging. On the other hand, imaging features may indicate certain pathologies. In this approach to the patient, we describe the case of a patient who presented with right temporal hemianopsia and a sellar/suprasellar cystic lesion, which was determined to be Rathke cleft cyst. We discuss the imaging characteristics that may suggest a particular diagnosis between Rathke cleft cyst, cystic pituitary adenoma, craniopharyngioma, and arachnoid cyst and propose a flowchart for aiding in the imaging differential diagnosis.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Rathke cleft cyst; craniopharyngioma; pituitary adenoma; sellar arachnoid cyst; sellar magnetic resonance imaging

Mesh:

Year:  2022        PMID: 35092687     DOI: 10.1210/clinem/dgac033

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Editorial: The progress of rare lesions of the sellar region.

Authors:  Congxin Dai; Run Yu; Haijun Wang; Justo P Castaño
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-24       Impact factor: 6.055

2.  Predictive factors for delayed hyponatremia after transsphenoidal surgery in patients with Rathke's cleft cysts.

Authors:  Kunzhe Lin; Zhijie Pei; Yibin Zhang; Tianshun Feng; Shousen Wang
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.